Medrad completes $361M purchase of Possis Medical

  
Medrad to expand cardiovascular intervention portfolio with Possis aquisition. Source: Medrad 
Bayer HealthCare affiliate Medrad has completed its tender offer for the outstanding shares of Possis Medical common stock.

Shares of the Minneapolis-based Possis were validly tendered in the offer and not withdrawn which, together with more than 700,000 shares to be tendered under guaranteed delivery procedures, represents approximately 92 percent of its outstanding common stock, Medrad said, through its subsidiary Phoenix Acquisition.

Last month, the Leverkusen, Germany-based Bayer reported its offering of $19.50 per share cash for Possis, was valued at approximately $361 million.

The Philadelphia-based Medrad, through its subsidiary Phoenix Acquisition, said it has accepted for purchase all shares that were validly tendered in the offer.

Possis supplies mechanical thrombectomy devices, which are used to treat narrowed or blocked blood vessels, and employees about 280 staff members.

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.